# Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

> **NCT02687711** · — · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 544 (actual)

## Conditions studied

- Epilepsy With POS With or Without Secondary Generalization

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02687711
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2021-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02687711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02687711, "Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT02687711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*